Tech Company Financing Transactions
Rigontec Funding Round
Boehringer Ingelheim Venture Fund, Forbion Capital Partners and High-Tech Gründerfonds participated in a $16.9 million Series A funding round for Rigontec. The round was announced on 9/7/2016.
Transaction Overview
Company Name
Announced On
9/7/2016
Transaction Type
Venture Equity
Amount
$16,879,575
Round
Series A
Investors
Proceeds Purpose
The funding will advance the ongoing development of Rigontec's RIG-I agonist platform targeting oncological, anti-infective and inflammatory indications as well as accelerate the progress of lead candidate RGT100 towards the clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Am Klopferspitz 19
Planegg, 82152
Germany
Planegg, 82152
Germany
Phone
Website
Email Address
Overview
Rigontec is the leader in RIG-I targeting RNA therapeutics. Utilizing our proprietary RIG-I agonist platform, we harness one of the most essential pathways in the innate immune system to pioneer a novel immuno-oncology treatment approach.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christian Schetter
Chief Financial Officer
Anne Burger
VP - R & D
Christine Schuberth-Wagner
Browse more venture capital transactions:
Prev: 9/7/2016: Sea Ltd. venture capital transaction
Next: 9/7/2016: Immune-Onc Therapeutics venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document every notable VC transaction. VC transactions reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs